MDMA-assisted Therapy for PTSD: Beyond Symptom Reduction (TRIPS)

November 11, 2022 | 12pm-1pm PST

w/ Ingmar Gorman, PhD

Buy a Ticket

About The Workshop

MDMA–assisted Therapy for post-traumatic stress disorder (PTSD) has been shown to reduce PTSD symptoms. However, an analysis of participants’ life enhancement through the treatment has not been closely examined. Using the construct of posttraumatic growth (PTG), we studied changes in self-perception, interpersonal relationships, and philosophy of life. MDMA-assisted psychotherapy for PTSD resulted in PTG and clinical symptom reductions of large-magnitude effect sizes. This presentation will be an overview of the rationale, findings, and future directions for MDMA-assisted therapy research beyond symptom reduction.


Meet Your Instructors

Ingmar Gorman, Ph.D.

Dr. Ingmar Gorman is a co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. As a psychologist, he shares his expertise in empirically supported psychedelic treatments with his clients and trainees alike. Dr. Gorman received his clinical training in New York City at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University. He simultaneously served as site co-principal investigator on an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and is currently a study therapist and supervisor on the same study. He is co-author on a Nature Medicine paper reporting the results of the first Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Dr. Gorman has also published on the topics of classic psychedelics, ketamine, and Psychedelic Harm Reduction and Integration.

Join us!

General Admission


Support our clinical trials!

  • Access to exclusive webinar setting with Thomas Kingsley Brown, Ph.D.
  • Free Access to Portland Psychotherapy Community Resources

About Therapy & Research in Psychedelic Science (TRIPS)

TRIPS seminar series hosts speakers discussing scientifically-oriented presentations and discussions about psychedelics to educate healthcare professionals. This series was created to guide healthcare providers and students preparing to be professionals towards the most relevant, pragmatic, and essential information about psychedelic-assisted therapy, changing legal statuses, and harm reduction approaches in order to better serve clients and communities.

This seminar series is a fundraiser for our clinical trial of MDMA-assisted psychotherapy for social anxiety disorder that Portland Psychotherapy investigators plan to begin in the Fall of 2021. All proceeds after presenter remuneration will go to fund this clinical trial.

These presentations are hosted through Zoom. Each presentation will be approximately 30 minutes with a 30-minute discussion afterward. Presentations will be recorded and sent to anyone who registers for the event. The recording will be available for 30 days after it has been sent to registered attendees.

Cancellation Policy: We charge a $10 administration fee for cancellations made by participants more than two weeks before the training event. For cancellations within two weeks of the training event, we will refund 50% of the tuition after subtracting the administration fee. Alternately, participants may elect to apply 100% of their tuition to a future TRIPS training event. No refunds will be given after training events.

Buy a Ticket